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A B S T R A C T
Objectives: To assess whether serum concentrations of saturated (SFAs), polyunsaturated (PUFAs), and mono-
unsaturated (MUFAs) fatty acids are associated with changes in blood pressure (BP) throughout pregnancy.
Study design: Prospective cohort.
Main outcome measures: Longitudinal measurements of systolic (SBP) and diastolic (DBP) BP.
Methods: Two hundred twenty-three healthy pregnant women were recruited in a public health center in Rio de
Janeiro, Brazil between 2009 and 2011. Fasting blood samples and BP measurements were obtained at the 1st
(5th–13th weeks), 2nd (20th–26th) and 3rd trimester (30th–36th). Crude and adjusted (maternal age, education,
energy intake, gestational body weight change, leptin concentrations, early pre-pregnancy BMI, leisure time
physical activity prior to pregnancy and linear and quadratic gestational weeks) longitudinal linear mixed-eﬀects
models were employed.
Results: SBP and DBP decreased from the 1st to the 2nd trimester and slightly increased from the 2nd to the 3rd
trimester (P < 0.001). In the adjusted model (ß and 95% CI), total SFAs [0.005 (0.001–0.008); P= 0.008], total
MUFAs [0.005 (0.001–0.009); P=0.019] and total n-6 PUFAs [0.005 (0.001–0.009); P= 0.025] were posi-
tively associated with SBP throughout pregnancy.
Conclusions: Maternal serum concentrations of total SFAs, MUFAs and n-6 PUFAs were positively associated with
BP levels in normotensive pregnant women.
1. Introduction
Physiological hemodynamic changes occur in the mother's body
during pregnancy to accommodate maternal and fetal demands.
Adaptations of the cardiovascular system include decreased vascular
resistance and increased blood volume and systolic (SBP) and diastolic
(DBP) blood pressure (BP) [1,2]. Studies have reported that maternal
SBP and DBP tend to decrease from the 1st to the 2nd trimester and
later increase progressively until delivery in uncomplicated pregnancies
[2,3].
Although these physiological adaptations are expected, BP levels are
inversely associated with birth weight and gestational age at birth, even
in normotensive women [4,5]. Given the importance of BP to the
pregnancy outcome, eﬀorts have been undertaken to elucidate factors
that may inﬂuence changes in BP during pregnancy. There is a growing
body of evidence supporting the hypothesis that poor placenta im-
plantation, mediated by systemic inﬂammatory response and en-
dothelial cells dysfunctions, accounts for hypertension during preg-
nancy [6].
Thus, maternal biomarkers associated with endothelial cell function
and the inﬂammatory response has the potential to be related to BP
changes during pregnancy [7]. Fatty acids (FAs) are important endo-
crine mediators that play a major role in the inﬂammatory process [8]
and vascular function in the oﬀspring [9] and may have diﬀerent
bioactive properties and functions depending on the number of un-
saturated bonds [10]. Greater intakes and levels of saturated fatty acids
(SFAs) have also been related with increased levels of low-density li-
poproteins (LDL-cholesterol) [11], thereby potentially contributing to
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an increased risk of developing cardiovascular disease [12]. However,
the results of a large randomized clinical trial (RCT) has cast doubt on
this ﬁnding [13]. In addition, observational trials and RCTs have re-
ported that higher intake of monounsaturated fatty acids (MUFAs) and
n-3 polyunsaturated fatty acids (PUFAs) may contribute to a decrease in
BP in adult populations [14,15].
It is well-known that serum concentrations of FAs are increased
during pregnancy [16]. Furthermore, studies have shown a high FA
requirement to ensure adequate embryo implantation and placenta
development [6]. Recent studies have also shown diﬀerences in n-3
PUFA concentrations in diﬀerent regions of the placenta among both
normotensive pregnancies and women with preeclampsia [17,18]. An
RCT that provided n-3 PUFAs as ﬁsh oils or ﬁsh meals have unequi-
vocally demonstrated a reduction in BP [19]. Lim et al. (2015) observed
an inverse association between maternal plasma concentrations of total
n-3 PUFAs and peripheral SBP in a study with 751 Chinese, Malay and
Indian pregnant women [20]. Intake of n-6 PUFAs has been associated
with increased pro-inﬂammatory eicosanoid levels in the general po-
pulation [21]. However, in vitro studies suggest that n-6 PUFA intake
may facilitate the early placentation process by stimulating angiogen-
esis in 1st trimester placental trophoblast cells [22,23,24].
Although there is previous evidence regarding the association be-
tween serum FAs and BP in the general population [14,15], we iden-
tiﬁed only one study that has investigated this association during
pregnancy [20]. We aimed to investigate whether concentrations of
various types of FAs during pregnancy were associated with BP
throughout gestation in normotensive pregnant women. We hypothe-
sized that during pregnancy, higher serum concentrations of MUFAs
and n-3 PUFAs would be associated with lower SBP and DBP, while
higher concentrations of SFAs and n-6 PUFAs would be associated with
higher SBP and DBP values.
2. Methods
This report describes a prospective cohort study of pregnant women
attending a prenatal care service oﬀered by a public health center in Rio
de Janeiro, Brazil. The enrollment of women occurred from November
2009 until October 2011, and the follow-up lasted until July 2012. The
study consisted of three follow-up visits, which occurred during the
5th–13th (1st trimester), 20th–26th (2nd trimester), and 30th–36th
(3rd trimester) gestational weeks.
A total of 322 women met the eligibility criteria [< 13 gestational
weeks; 20–40 years old; no chronic diseases (aside from obesity)] and
were invited to participate. From those 322 women, 23 women chose
not to participate, and 76 women were excluded after enrolment for the
following reasons: were diagnosed with chronic diseases (n=12) or
with infectious diseases (n=9), had advanced pregnancy (≥14weeks
of gestation) (n=15), had multiple pregnancies (n= 4), missed the
baseline interview (n=5) or the baseline blood collection (n= 6) or
suﬀered early miscarriages (n= 25). The baseline sample consisted of
223 pregnant women. From the baseline to the 2nd trimester visit, 19
additional exclusions occurred, and 15 follow-up losses occurred, with
189 women remaining at the 2nd trimester visit. Two women dropped
out between the 2nd and 3rd visits. In addition, an RCT was nested
within the cohort starting after the 2nd trimester and lasting until de-
livery. The RCT aimed to investigate the eﬀect of n-3 PUFA supple-
mentation on postpartum depression (ClinicalTrials.gov:
NCT01660165). Forty-one out of 189 women were randomized and
received six gelatin capsules per day containing ﬁsh oil (n= 20) or
placebo (soybean oil, n= 21). Six women out of 41 did not adhere to
the RCT and were analyzed at the 3rd trimester visit, while 35 women
who adhered to the RCT were excluded from the 3rd trimester analysis
with a ﬁnal remaining sample of 152 women in the 3rd trimester
(Fig. 1) [25].
2.1. Blood samples
Blood samples were obtained at the 1st (5th-13th weeks), 2nd
(20th-26th) and 3rd trimester (30th–36th) after 12 h of fasting, and
were collected in vacutainer tubes and immediately centrifuged (5,031g
for 5min) within 1 h. Aliquots of serum (prepared from blood collected
into tubes with a gel separator) were stored at −80 °C until analyses.
Serum samples were used to determine the FA compositions.
2.2. Fatty acid concentrations
Analyses of serum FA composition were performed in the Section of
Nutritional Neuroscience, Laboratory of Membrane Biochemistry and
Biophysics of the National Institute of Health (NIH/USA). Serum sam-
ples were shipped from Brazil to the NIH/USA in boxes with dry ice.
High-throughput robotic direct methylation, coupled with fast gas-
liquid chromatography, was used to identify the serum FAs. This
technique was developed and validated by the NIH to allow analysis on
a large scale [26]. The analyses were performed using a chromatograph
HP 6890 Plus gas LAN equipped with three ﬂame ionization detectors
(Agilent Technologies, Santa Clara, CA, USA) coupled to a fused silica
capillary column (Agilent 127-32H2 15m×0.1mm×0.1mm).
Twenty-two FAs were measured: 14:0, 16:0, 16:1n-7, 18:0, 18:1n-9,
18:1n-7, 18:2n-6, 18:3n-6, 18:3n-3, 20:0, 20:1n-9, 20:2n-6, 20:3n-6,
20:4n-6, 20:5n-3, 22:0, 22:4n-6, 22:3n-3, 22:5n-3, 24:0, 22:6n-3, and
24:1n-9. Although we measured 22 FAs, we opted to present only n-3
and n-6 fractions plus totals for MUFAs, SFAs, and PUFAs, considering
the representativeness of these fractions [27]. FAs were presented in
absolute values (µg/mL).
2.3. Blood pressure
BP was measured twice at all follow-up visits (5th–13th, 20th–26th,
and 30th–36th gestational weeks) with approximately 30-min intervals
between measurements. The mean values obtained from each follow-up
visit were calculated and considered in the analysis. Measurements
were performed using an automated oscillometric BP monitoring
system (Omron HEM-742, São Paulo, Brazil), which was previously
validated [28] using an adequate cutoﬀ that ﬁt the upper arm’s cir-
cumference. Prior to measuring BP, women were asked to rest for at
least ﬁve minutes and to be seated comfortably with their backs sup-
ported, legs uncrossed, and feet ﬂat on the ﬂoor, remaining silent
during the procedure. The arm with the cuﬀ was supported at the heart
level, with the palm facing up and the elbow slightly ﬂexed.
2.4. Covariates assessment
A structured questionnaire was administered by trained inter-
viewers at each pregnancy trimester to determine the women’s socio-
demographic and lifestyle characteristics, including age (years), edu-
cation (years), and practice of leisure time physical activity prior to
pregnancy (yes/no). Total energy intake (kcal/d) was obtained using a
validated food frequency questionnaire (FFQ), which used the previous
six months’ pregnancy as the time frame. The FFQ was administered at
baseline [29].
Weight was measured in each visit using an electronic scale
(Filizzola Ltd., São Paulo, Brazil), calibrated to the nearest gram. Height
was measured in duplicate using a portable stadiometer (Seca Ltd.,
Hamburg, Germany) at baseline. Early pregnancy body mass index
(BMI) [weight (kg)/height (m)2] was determined based on the weight
and height measured before the 13th gestational week. Women were
classiﬁed according to early pregnancy BMI as either normal weight
(18.5 < BMI≤ 24.9 kg/m2), overweight (25≤ BMI≤ 29.9 kg/m2), or
obese (BMI≥ 30 kg/m2). Trained staﬀ performed anthropometric
measures using standardized procedures [30].
Gestational age was estimated by ultrasound if performed prior to
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24 gestational weeks (n= 221). Otherwise, the reported date of the last
menstrual period was used to calculate the gestational age (n=2).
Plasma leptin concentrations were determined using a human-spe-
ciﬁc enzyme linked immunosorbent assay (ELISA) method (Millipore,
St. Charles, Missouri, USA) with a sensitivity of 0.5 ng/dl. All proce-
dures were performed following the manufacturer’s instructions in
duplicate.
2.5. Statistical analysis
The Shapiro–Wilk W-test was the statistical procedure used to assess
the normality of the variables. We compared the mean concentrations
of FAs and the socio-economic proﬁles of pregnant women that reached
the ﬁnal follow-up (n=152) with those that were considered losses of
follow-up or exclusions (all combined, n= 71) using the chi-square test
for categorical variables and Student’s t-test for continuous variables.
The women’s general characteristics were described with the mean
and standard deviation. Mean SBP and DBP throughout pregnancy were
compared using ANOVA for repeated measures. The mean values of SBP
and DBP throughout pregnancy were calculated according to baseline
tertiles of the FA (µg/mL) distribution. We also adopted tertiles because
there are no established cut-oﬀ points for FA distribution. In each tri-
mester of pregnancy, we compared the mean in each tertile of SBP and
DBP using ANOVA. The Bonferroni test was employed as the main post
hoc test to compare means of SBP and DBP in each trimester according
to baseline FA tertiles (P-value < 0.05) [31].
Longitudinal linear mixed-eﬀects (LME) regression models were
performed to evaluate the association between FA concentrations and
BP changes during pregnancy. The LME models capture inter- and intra-
individual changes, considering that repeated measures of the same
individual are correlated, and the models accommodate time- depen-
dent and independent covariates and enable non-equidistant intervals
[32]. Bivariate models were adjusted for gestational age (linear and
quadratic). Quadratic gestational week was considered due to the
parabolic BP pattern of variation during pregnancy. All models were
ﬁtted using the unstructured covariance matrix for random eﬀects
(intercept and slope). Confounders were added to the model based on
biological plausibility and statistical signiﬁcance in bivariate regression
models (P < 0.2) with both the main exposure, FA concentrations, and
outcome BP. Multivariate models were later adjusted for maternal age,
education, energy intake, gestational body weight change, leptin con-
centrations, early pre-pregnancy BMI, leisure time physical activity
prior to pregnancy and linear and quadratic gestational weeks. The
residual distribution of the multiple longitudinal models was conﬁrmed
using scatter and quantile-quantile plots of residuals and plots to check
the potential autocorrelation structure. We performed independent
models for each serum FA.
Eﬀect plots containing data scatter, longitudinal prediction, and
95% conﬁdence intervals (CIs) were constructed to illustrate the var-
iation in SBP and DBP during pregnancy according to tertiles of total
SFAs, MUFAs, and n-3 and n-6 PUFAs.
Stata Data Analysis, version 12.0 (Stata Corp., College Station,
Texas, USA), and R statistical software package, version 3.1.2 were used
to perform the statistical analyses.
2.6. Ethical approval
The Ethics Committee of the Maternity Hospital (protocol:
0023.0.361.00-08) and Institute of Psychiatry (protocol:
0012.0.249.000-09) from the Rio de Janeiro Federal University ap-
proved the study protocol. The Ethics Committee of the Municipal
Secretary of Rio de Janeiro City also approved the study (protocol:
0139.0.314.000-09). All women provided their written informed con-
sent (see Table 1).
Nested Randomized clinical 
trial (RCT)
41 women were randomized
20 for omega 3 (fish oil) group
21 for placebo (soybean oil) group
152
Participants in the 3rd
trimester (30th-36th)
analyzes
189
Participants in the 2nd
trimester (20th-26th)
analyzes
6 women did not 
adhere the RCT
2 Follow-up losses
1 moved out of the program
1 abandoned pre natal care
15 Follow-up losses
10 moved out of the program
5 abandoned pre natal care
223
Participants in the 1st
trimester (5th-13th)
analyzes
19 additional exclusions 
2 women with SBP 140 
mmHg and/or DBP  90 
mmHg after enrollment 
17 missing information of
fatty acids or blood pressure
76 women were excluded
12 with a confirmed pre-pregnancy diagnosis of chronic non-communicable diseases
9 with infectious diseases
15 advanced pregnancy (14weeks of gestation)
4 multiple gestation
5 missed the baseline interview
6 missed the baseline blood collection
25 miscarriages
299
Agreed to participate
23 chose to not 
participate in the study
322 pregnant women
Met the eligibility criteria and were invited to participate
Fig. 1. Flowchart illustrating the process of recruitment and follow-up of study participants.
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3. Results
No diﬀerences were observed regarding FA proﬁle concentrations
and other co-variables among women who completed the follow-up
compared to those classiﬁed as lost to follow-up (Supplemental
Table 1).
The mean SBP values presented similar trends according to tertiles
of total SFAs concentrations throughout pregnancy. We observed a
decrease from the 1st to the 2nd trimester and an increase at the 3rd
trimester. However, those women classiﬁed in the 3rd tertile had higher
mean values of SBP in the 1st trimester (P= 0.048) and 3rd trimester
(P= 0.04) compared to those in the 1st and 2nd tertiles. Women in the
3rd tertile of total PUFAs n-6 also had higher means of SBP (P= 0.03)
and DBP (P= 0.03) compared to those classiﬁed in the 1st tertile at the
1st trimester. At the 1st pregnancy trimester, higher DBP was associated
with total n-3 PUFA tertiles (P= 0.04) but not during the 2nd or 3rd
trimesters (Supplemental Tables 2 and 3).
Women in the 3rd tertile of total SFAs and total n-6 PUFAs had
signiﬁcantly higher SBP throughout pregnancy compared to women in
the 1st tertile. Similar associations were found for DPB (Fig. 2).
The concentrations of totals SFAs, MUFAs and n-6 PUFAs were
positively and signiﬁcantly associated with SBP during pregnancy in
both crude and adjusted models. However, no associations were ob-
served with DBP (Table 2).
4. Discussion
The present study has two primary ﬁndings. First, we observed that
total SFAs, total MUFAs and total n-6 PUFAs concentrations were po-
sitively associated only with SBP. These analyses remained statistically
signiﬁcant after adjustment for potential confounders, such as maternal
age, education, energy intake, gestational body weight change, leptin
concentrations, early pre-pregnancy BMI, leisure time physical activity
prior to pregnancy and linear and quadratic gestational weeks. Second,
we observed that pregnant women who classiﬁed into the highest tertile
of SFAs (values≥ 779.4 µg/mL) at baseline had signiﬁcantly higher
SBP and DBP values in the 1st trimester and 3rd trimester compared to
those in the 1st and 2nd tertiles.
Total SFAs were positively and signiﬁcantly associated with SBP.
Our results are consistent with a retrospective study involving 55
middle-aged adults studied by Kim et al. [33]. These authors observed
that total SFAs, 14:0, 16:0, and 18:0 were positively and signiﬁcantly
correlated with SBP and DBP [33]. In addition, studies conducted with
animals and humans have reported that SFAs concentrations play an
important role on the regulation of endothelial function [8,9]. We
suspect that this mechanism could partially explain our results. While
the etiology of gestation hypertension remain unclear, our results may
contribute to the elucidation of factors associated with BP changes
throughout pregnancy.
We also observed that MUFA concentrations were positively asso-
ciated with SBP levels during pregnancy. To the best of our knowledge,
no previous studies have reported this longitudinal association among
pregnant women. Among adult non- pregnant populations, previous
observational and RCT studies reported contrasting results compared to
our study, i.e., a higher intake of MUFAs contributed to the control of
BP and prevention of hypertension in adult populations [14]. Miura
et al. [14] observed a signiﬁcant inverse relationship of total MUFAs
intake with DBP in a sample of 4680 male and female adults
(−0.82mmHg) from China, Japan, the UK, and the USA. In contrast, a
signiﬁcant increase of 1.70mmHg in DBP was found for those who were
not following a special diet, did not consume nutritional supplements
and were not diagnosed with chronic disease. Several other studies
have shown similar results in the general population [34,35] as the ones
presented by Miura et al. [14]. The lack of consensus for the above
association may be partially explained because diﬀerent types of de-
signs were used. Furthermore, it is possible that in observational stu-
dies, such as the current one, the endogenous production of carbohy-
drates and the excess of calorie intake is the MUFA source, and the
increased intake of MUFAs may have beneﬁcial eﬀects [35].
It is important to emphasize that our sample consists of normoten-
sive pregnant women, and comparisons with available literature is
limited. In apparent contrast to our ﬁndings, the more highly un-
saturated n-3 PUFAs appear to be inversely associated with BP in adult
populations [36]. The eﬀects of n-3 PUFAs are likely to occur due to
several mechanisms, including reduced inﬂammation, improvement in
vascular endothelial function, and increased nitric oxide production,
eﬀects that are well- demonstrated in adults [15,24,36]. However, in
contrast with our results, a cross- sectional study with normotensive
pregnant women showed an inverse association with n-3 PUFAs con-
centrations and SBP (OR: −0.51, 95%CI: 92 to −13), even after ad-
justing for maternal age, ethnicity, education level, exercise, smoking,
alcohol intake before or during pregnancy, BMI, gestational diabetes,
heart rate and use of ﬁsh oil supplements [20].
Adequate FAs levels during the prenatal and early periods of preg-
nancy are essential for placenta development and to maintain maternal
concentrations. Severe deﬁcits may have permanent eﬀects if they
occur during critical periods of early development [2,21]. FAs are
biologically active components that regulate placental angiogenesis,
inﬂammation, and oxidative stress [23,37].
A strength of this study lies in its novelty. To the best of our
knowledge, this report describes the ﬁrst longitudinal study to in-
vestigate the association between serum FAs and BP during pregnancy.
Moreover, our longitudinal design and the robustness of the statistical
analysis allowed us to assess BP and FA concomitant changes
throughout the gestational period and to consider the data as repeated
measures [32]. Another strength is the use of serum compositions of
FAs, which is considered to be more accurate than dietary data assessed
in previous studies with FFQ [14,15]. The study participants’ losses to
follow-up (7.6%) might be a study limitation, although these losses are
expected in prospective studies. However, we observed that these losses
were randomly distributed for the variables of interest. Furthermore,
because women were excluded from our sample if they developed hy-
pertension (n= 2), the association between FAs levels and BP in this
analysis may have been relatively weakened. Nevertheless, it is worth
mentioning that we were able to show statistically signiﬁcant associa-
tions between FAs and BP, even considering only normotensive women.
This information adds relevant knowledge in the context of prevention
of gestational hypertensive disorders.
In conclusion, the present study observed that total serum SFAs
were positively associated with SBP pregnancy. We also observed that
Table 1
General characteristics of women.1
n All
Age, y 223 26.6 ± 5.4
Education, y 223 8.6 ± 2.9
Per-capita family income, US$2 216 311.7 ± 190.5
Early body mass index, kg/m2 223 24.6 ± 4.8
Total gestational weight gain, kg2 201 13.0 ± 5.6
Energy intake, kcal/d 223 2,407 ± 886
n All P3
Systolic blood pressure, mmHg
1st trimester 223 110.2 ± 9.2
2nd trimester 189 108.9 ± 9.1 < 0.001
3rd trimester 152 111.2 ± 9.6
Diastolic blood pressure, mmHg
1st trimester 223 67.1 ± 7.6
2nd trimester 189 65.0 ± 6.7 < 0.001
3rd trimester 152 66.8 ± 7.2
1 Values are means ± standard deviation.
2 Variables with missing values.
3 P refers to comparison of means with ANOVA for repeated measures.
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Fig. 2. Longitudinal prediction of SBP and DBP levels according to tertiles of FAs during pregnancy. A - Total saturated fatty acids. B - Total monounsaturated fatty
acids. C - Total n-6 fatty acids. D - Total n-3 fatty acids. Note: Fatty acids were categorized in tertiles of the sample distributions and 1st tertile was the reference
category. The models were adjusted for age, education, energy intake, gestational body weight change, leptin concentrations, pre-pregnancy BMI, leisure time
physical activity, linear and quadratic gestational weeks. Data are presented as linear mixed eﬀect coeﬃcient (β) and 95% CI. P refers to the maximum likelihood
estimator A - SBP: 2nd tertile β=1.8 (−0.6–4.3), P= 0.146; 3rd tertile β=2.6 (0.2–5.1), P=0.033. DBP: 2nd tertile β=2.0 (0.1–4.0), P=0.042; 3rd tertile
β=1.8 (−0.1–3.8), P= 0.064. B - SBP: 2nd tertile β=1.9 (−1.7–5.5), P= 0.312; 3rd tertile β=1.4 (−1.1–3.9), P= 0.276. DBP: 2nd tertile β=1.5 (−0.5–3.5),
P=0.135; 3rd tertile β=0.6 (−1.4–2.6), P= 0.574. C - SBP: 2nd tertile β=1.7 (−0.7–4.1), P=0.165; 3rd tertile β=2.5 (0.1–4.9), P=0.045. DBP: 2nd tertile
β=1.7 (−0.2–3.7), P= 0.083; 3rd tertile β=1.8 (−0.1–3.8), P= 0.068. D - SBP: 2nd tertile β=−1.3 (−3.7–1.1), P= 0.296; 3rd tertile β=1.4 (−1.1–3.9),
P=0.264. DBP: 2nd tertile β=−0.99 (−2.9–1.0), P= 0.346; 3rd tertile β=1.0 (−1.0–3.0), P= 0.352.
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the total SFAs, total MUFAs and total n-6 PUFAs were positively and
signiﬁcantly associated with SBP. Given the importance of gestational
hypertensive disorders to maternal and fetal health and given the
scarcity of studies investigating this association, eﬀorts should be un-
dertaken to elucidate factors that may inﬂuence changes in BP during
pregnancy.
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